Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIAT
Ratios

Coherus Oncology (CHRS) Long-Term Debt Repayments (2022)

Historic Long-Term Debt Repayments for Coherus Oncology (CHRS) over the last 1 years, with Q1 2022 value amounting to $109.0 million.

  • Coherus Oncology's Long-Term Debt Repayments changed N/A to $109.0 million in Q1 2022 from the same period last year, while for Dec 2022 it was $109.0 million, marking a year-over-year change of. This contributed to the annual value of $260.4 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q1 2022, Coherus Oncology's Long-Term Debt Repayments is $109.0 million.
  • In the past 5 years, Coherus Oncology's Long-Term Debt Repayments ranged from a high of $109.0 million in Q1 2022 and a low of $109.0 million during Q1 2022